
Professor Julie Fox
Lead Investigator
- Reader HIV
Research interests
- Immunology
- Preventative medicine
Biography
Professor Julie Fox qualified from the University of Manchester and trained in Genitourinary Medicine at Imperial College London. Julie leads the HIV clinical trials unit at Guys and St Thomas’ NHS Trust and is a Professor in HIV Infection in the School of Immunology & Microbial Sciences at King's. Julie is also Chief Investigator on national and international multi-centre intervention studies collaborating with NHS/academic partners across the UK, Europe and Sub-Saharan Africa.
Her research focuses on HIV prevention (vaccine and pre-exposure prophylaxis), HIV cure and optimising HIV treatment. She collaborates widely and is a keen proponent of multidisciplinary research. Julie is co-founder of the UK HIV cure group: Collaborative HIV Eradication of Reservoirs: UK BRC (CHERUB) and leads the international combined HIV adolescent prevention group, CHAPS. Furthermore, she is trial physician of the international HIV vaccine and PrEP study, PREPVACC.
In the past year, Julie has carried out SARS-CoV-2 research. In addition, she co-led the HIV group of the Oxford COV002 vaccine trial and is leading a multidisciplinary research network across UK, Uganda and South Africa evaluating SARS-CoV-2 antibody evolution, developing a SARS-CoV-2 ex vivo challenge model and carrying out public engagement in rural communities (COVAB). She is Chief investigator of the COV-TT test and treat study and is collecting longitudinal samples from special populations to evaluate antibody response to vaccination (COVAB-B).
Research

Fox Group
The Fox Group works on combined HIV adolescent prevention and investigating COVID-19 infectiousness and antibody evolution in COVID-19 patients in Sub-Saharan Africa and Europe.

CHAPS (Combined HIV Adolescent Prevention Study)
Combined HIV African Prevention Study: On-demand Truvada and F/TAF Pre-exposure and Post-exposure prophylaxis to protect adolescents from HIV
News
King's study provides vital information to guide COVID-19 vaccine development
The researchers examined antibodies from people who had recovered from COVID-19 in multiple countries.

Spotlight
Preventing new HIV infections through vital medication guidelines
Research by King’s provides vital evidence on the efficacy of pre-exposure prophylaxis (PrEP)

Research

Fox Group
The Fox Group works on combined HIV adolescent prevention and investigating COVID-19 infectiousness and antibody evolution in COVID-19 patients in Sub-Saharan Africa and Europe.

CHAPS (Combined HIV Adolescent Prevention Study)
Combined HIV African Prevention Study: On-demand Truvada and F/TAF Pre-exposure and Post-exposure prophylaxis to protect adolescents from HIV
News
King's study provides vital information to guide COVID-19 vaccine development
The researchers examined antibodies from people who had recovered from COVID-19 in multiple countries.

Spotlight
Preventing new HIV infections through vital medication guidelines
Research by King’s provides vital evidence on the efficacy of pre-exposure prophylaxis (PrEP)
